longbridgelongbridge
  • Products
  • Fees
  • Download
  • Promotions
    Welcome RewardsReferral ProgramUS Pre-Market Options Trading
  • For Institutions
    Corporate ServicesDevelopers
  • Help
  • About
    About LongbridgeLicense & RegulatoryMedia CoverageJoin Us
longbridge
  • Home
  • Discover
    Discover
    Global MarketsStock ScreenerFinancial Calendar
  • News & Info
    News & Info
    NewsInsightsLiveAcademy
  • Watchlist
  • Trade
  • Notification
  • LongbridgeAI
Home
Discover
News & Info
Watchlist
Trade
LongbridgeAI
Quote ListQuote List

ALTAMIRA THERAPEUTICS LTD(CYTOF.US)

Last Updated 19:00:00 ET
longbridge loading
News
Financials
Overview

Vax appoints James B. Breitmeyer to its Board

TradingView·04/24/2026 04:53
US
CYTOF
0.00%
US
VXRT
-1.66%
US
SBIO
+2.81%
TradingView·04/24/2026 04:53
US
CYTOF
0.00%
US
VXRT
-1.66%
US
SBIO
+2.81%

GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs

businessinsider·03/28/2026 21:57
US
GRTX
+7.04%
US
NBSE.ESC
0.00%
US
IHE
+0.32%
businessinsider·03/28/2026 21:57
US
GRTX
+7.04%
US
NBSE.ESC
0.00%
US
IHE
+0.32%

US Weekly Recap: Aerospace and healthcare issuers drive late-March filing activity

RenaissanceCapital·03/28/2026 06:24
US
IPFXU
0.00%
US
SBIO
+2.81%
US
CYTOF
0.00%
RenaissanceCapital·03/28/2026 06:24
US
IPFXU
0.00%
US
SBIO
+2.81%
US
CYTOF
0.00%

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress | GDTC Stock News

StockTitan·01/28/2026 15:00
US
BBH
+0.22%
US
SBIO
+2.81%
US
GDTC
+2.07%
StockTitan·01/28/2026 15:00
US
BBH
+0.22%
US
SBIO
+2.81%
US
GDTC
+2.07%
© 2026 Longbridge|Disclaimer

Event Tracking

Mar31
Altamira Therapeutics Reports Reduced Net Loss in 2025 Fiscal Year
21:37
Mar24
ALTAMIRA THERAPEUTICS LTD to Release FY2025 Annual Earnings on March 31, 2026 Pre-Market EST
00:10
Dec19
Altamira Medica Receives NMPA Market Approval for Bentrio Nasal Spray
14:00
Nov20
Altamira Medica Obtains EU MDR Certification for Bentrio Nasal Spray
14:01
Aug30
Altamira Therapeutics Ltd released FY2025 Q1 earnings on August 29 (EST), actual revenue USD 0, actual EPS USD -0.1529
03:00
Aug29
Altamira Therapeutics Ltd released FY2025 Semi-Annual Earnings on August 29 Pre-Market (EST), Actual Revenue: USD 0 (Forecast: USD 0), Actual EPS: USD -0.3059 (Forecast: USD --)
13:30

Schedules & Filings

Schedules
Filings
Mar31
Earning Release(EST)

FY2025 Annual Earning Release

Aug29
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -767.51 K, EPS -0.1529

Apr30
Earning Release(EST)

FY2024 Q4 Earning Release (USD) Net Income -2.059 M, EPS -0.5713

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
OPTH
6.120
+2,502.04%
+5.885
HCWB
2.530
+138.68%
+1.500
FSHPR
0.1666
+105.43%
+0.086
MWC
8.650
+83.26%
+3.930
GCL
0.7523
+74.26%
+0.321
SLXN
0.4423
+64.42%
+0.171
EMISR
0.1400
+39.86%
+0.040
PETZ
1.131
+39.63%
+0.323
HSPTR
0.3100
+39.01%
+0.087
CELG.RT
0.1499
+38.80%
+0.042
View More